DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

Angiogenesis as a strategic target for ovarian cancer therapy. — Alliance for NanoHealth
Navigation
 
 
 
You are here: Home Research Publications Angiogenesis as a strategic target for ovarian cancer therapy.
Document Actions

WA Spannuth, AK Sood, and RL Coleman (2008)

Angiogenesis as a strategic target for ovarian cancer therapy.

Nat Clin Pract Oncol. 5(4):194-204.

Angiogenesis is a complex and highly regulated process that is crucial for tumor growth and metastasis. Insights into the molecular mechanisms of tumor angiogenesis have led to the identification of potential angiogenic targets and the development of novel antivascular agents. Many of these agents are being evaluated in clinical trials and have shown promising antitumor activity. This Review highlights the results of the latest clinical studies of antivascular agents in ovarian cancer and discusses the challenges and opportunities for future clinical trials.